BRIGHT GREEN ANNOUNCES PLANS FOR $250 MILLION EXPANSION OF ITS CONTROLLED SUBSTANCES DRUG PRODUCTION FACILITY IN GRANTS, NEW MEXICO AND OBTAINS $60 MILLION IN FINANCING
- None.
- None.
Insights
The announcement by Bright Green Corporation of a significant expansion of its research, production and extraction processing facility represents a strategic endeavor to strengthen its manufacturing capabilities in the pharmaceutical sector. The planned addition of 7 million square feet is a substantial increase in infrastructure, which could potentially lead to increased production capacity and a more robust product pipeline. The modular construction approach indicated by the Dalsem Agreement suggests a scalable and potentially more cost-efficient expansion process.
Furthermore, the funding structure, combining senior debt financing with EB-5 investment visa capital, demonstrates a diversified approach to financing, which can mitigate risks associated with over-reliance on debt. The fixed interest rate and tranched draw schedule of the Credit Agreement provide a predictable financial obligation, which can be crucial for long-term financial planning and stability. However, the dependency on EB-5 capital could introduce variability, as it is contingent on foreign investment inflows, which can be influenced by geopolitical and economic factors.
The DEA and State of New Mexico Board of Pharmacy's approval for Bright Green to produce Schedule I and II controlled substances is a significant milestone, as it positions the company as a pioneer in domestic controlled substance production. This approval could reduce the United States' reliance on foreign imports for critical pharmaceutical ingredients and finished products, addressing national security concerns regarding supply chain vulnerabilities. The 'Drugs Made in America' initiative could resonate with current policy efforts to bolster domestic manufacturing and could lead to preferential treatment or support from government entities.
The emphasis on low-cost generic drug manufacturing and the integration of solar power technology aligns with broader industry trends towards sustainability and cost reduction. The potential for state and federal tax credits could provide a financial advantage and improve the company's competitive positioning. However, the success of this initiative will depend on the company's ability to deliver on its promises of cost reduction and maintain quality standards that are competitive with global players.
The commitment to solar energy use for powering the facility is indicative of Bright Green's alignment with ESG principles, which are increasingly important to investors. The carbon-neutral footprint could not only enhance the company's reputation but also appeal to a growing segment of socially responsible investors. The potential for unprecedented state and federal tax credits for utilizing renewable energy sources could improve the company's financials and offer a unique selling proposition in comparison to competitors.
However, the actual ESG impact will depend on the implementation and operational efficiency of the solar power generation field. Investors and stakeholders will likely monitor the long-term sustainability of these initiatives and their tangible impact on the company's carbon footprint and operational costs. The rural location of the company may present both challenges and opportunities, with potential cost savings on land and construction potentially offset by logistical considerations.
GRANTS, NEW MEXICO, March 12, 2024 (GLOBE NEWSWIRE) -- Bright Green Corporation (Nasdaq: BGXX) (“Bright Green” or the “Company”) today announced that it has signed an agreement with Dalsem Greenhouse Technologies BV for a
Additionally, the Company has entered into a credit agreement with a lender for a
This expansion is a direct result of Bright Green obtaining the regulatory approvals for the production of Schedule I and II controlled substances from the DEA and the State of New Mexico Board of Pharmacy. The expansion will facilitate the production and manufacturing required to process the active pharmaceutical ingredients (“API”) and to make generic prescription drugs, supporting Bright Green's “Drugs Made in America” initiative.
Lynn Stockwell, Bright Green’s Chairwoman said “This cutting-edge bespoke greenhouse project incorporates state of the art technology and is designed with a modular approach. The number of modules constructed at any given time is contingent upon the capital from our EB-5 investors and other federal infrastructure assistance. I am also pleased to confirm that this project will be powered by energy from solar panels with the components soon to be produced here in Albuquerque. Ms. Stockwell continues “shareholders will benefit from a producer/manufacturer with a solar power generation field as the state and federal tax credits are unprecedented allowing our rural based company significant advantages over foreign competition resulting in a low-cost generic drug manufacturing company and importantly, leaving a carbon neutral footprint.”
CEO Groovy Singh expressed his optimism for the impact the expansion will have for its “Drugs Made In America” plan. Mr, Singh shared that “Bright Green is the first company in almost a century to receive approval to produce these controlled substances in the U.S., so this is a new concept for the U.S. pharmaceutical industry. The opportunity to mitigate the national security risk associated with dependency on foreign imports—manufactured in countries that may have different ideologies and quality standards that practiced by U.S companies—is to substantial to ignore.”
The company is finalizing negotiations for the necessary services from the city, landowners' land parcels and the necessary state permitting for the construction and occupancy.
The company believes the fully integrated approach in rural Grants, New Mexico will substantially reduce the costs of drugs to both the state and all Americans.
About Bright Green Corporation
Bright Green is one of the very few companies selected by the New Mexico Board of Pharmacy and the US government for the production, API and drug manufacture, market and distribute Schedule 1-V plant-based drugs API including opium, cannabis and cannabis-related products for research, pharmaceutical applications, and affiliated export. Our approval based on already agreed terms from the U.S. Drug Enforcement Administration gives us the opportunity to advance our vision of improving quality of life through the opportunities presented by cannabis-derived therapies. To learn more, visit www.brightgreen.us.
Cautionary Note Regarding Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These forward-looking statements are made as of the date they were first issued and were based on current expectations, estimates, forecasts and projections as well as the beliefs and assumptions of management as of such date. Words such as “expect,” “anticipate,” “should,” “believe,” “hope,” “target,” “project,” “goals,” “estimate,” “potential,” “predict,” “may,” “will,” “might,” “could,” “intend,” “shall” and variations of these terms or the negative of these terms and similar expressions are intended to identify these forward-looking statements. Forward-looking statements are subject to a number of risks and uncertainties, many of which involve factors or circumstances that are beyond the Company’s control, including but not limited to, the inability of the Company to raise funds under the Company’s EB-5 program, and the impact that new officers, directors and employees may have on the Company and the Company’s business and results of operations. The Company’s actual results could differ materially from those stated or implied in forward-looking statements due to a number of factors, including but not limited to, risks detailed in the Company’s Annual Report on Form 10-K and Quarterly Report on Form 10-Q, as amended and supplemented, as well as other documents that may be filed by the Company from time to time with the SEC. The forward-looking statements included in this press release represent the Company’s views as of the date of this press release. The Company anticipates that subsequent events and developments will cause its views to change. The Company undertakes no intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. These forward-looking statements should not be relied upon as representing the Company’s views as of any date after the date of this press release. Additional information regarding these and other factors that could affect the Company’s results is included in the Company’s SEC filings, which may be obtained by visiting the SEC's website at www.sec.gov.
Media Contacts: Interdependence Public Relations Owen Phillips / Grace Connor BrightGreen@Interdependence.com
(310) 745-1407
Media Inquiries & Investor Relations Contact
ir@brightgreen.us
FAQ
What is the purpose of the $250 million construction project announced by Bright Green Corporation (Nasdaq: BGXX)?
How much senior debt financing has Bright Green secured for the expansion project?
What funding source is expected to complement the senior debt financing for the expansion project?
What regulatory approvals have allowed Bright Green to proceed with the expansion project?
How will the expansion support Bright Green's 'Drugs Made in America' initiative?
